Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
Latest Information Update: 25 Mar 2024
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
Most Recent Events
- 19 Mar 2024 Status changed from active, no longer recruiting to completed.
- 02 Nov 2019 This trial has been discontinued in Germany as per European Clinical Trials Database record.
- 14 Feb 2018 Status changed from recruiting to active, no longer recruiting, according to a Vanda Pharmaceuticals media release.